Inventor · disambiguated record
David Munn
Also filed as: MUNN DAVID · MUNN DAVID H
12 granted patents·16 pending applications·190 citations·filing 1998–2017
92Inventor score
Files withMED COLLEGE GEORGIA RES INST9MUNN DAVID4MED COLLEGE OF GEORGIA RES INS2MELLOR ANDREW L2MUNN DAVID H2
Top patents by PatentIndex Score
28 records- 0196US6482416B2Regulation of T cell-mediated immunity by tryptophanMED COLLEGE GEORGIA RES INST·Filed 2000·Granted Nov 19, 2002·57 cites·13 claims
- 0289US8232313B2Pharmaceutical compositions containing 1-methyl-D-tryptophanMUNN DAVID·Filed 2008·Granted Jul 31, 2012·14 cites·16 claims
- 0388US7598287B2Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalitiesMED COLLEGE GEORGIA RES INST·Filed 2004·Granted Oct 6, 2009·21 cites·17 claims
- 0488US6451840B1Regulation of T cell-mediated immunity by tryptophanMED COLLEGE GEORGIA RES INST·Filed 1998·Granted Sep 17, 2002·42 cites·5 claims
- 0587US8580844B2Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalitiesMUNN DAVID·Filed 2009·Granted Nov 12, 2013·4 cites·5 claims
- 0684US7160539B2Regulation of T cell-mediated immunity by tryptophanMEDICAL COLLEGE OF GEORGIA·Filed 2002·Granted Jan 9, 2007·20 cites·10 claims
- 0775US7879791B2Regulation of T cell-mediated immunity by tryptophanMED COLLEGE GEORGIA RES INST·Filed 2006·Granted Feb 1, 2011·3 cites·15 claims
- 0874US8198265B2Regulation of T cell-mediated immunity by tryptophanMUNN DAVID·Filed 2006·Granted Jun 12, 2012·3 cites·7 claims
- 0969US6395876B1High-affinity tryptophan transporterMED COLLEGE GEORGIA RES INST·Filed 1998·Granted May 28, 2002·20 cites·7 claims
- 1068US7465448B2Chemokine receptor antagonists as therapeutic agentsMED COLLEGE GEORGIA RES INST·Filed 2003·Granted Dec 16, 2008·6 cites·5 claims
- 1167US9463239B2Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalitiesGEORGIA REGENTS RES INST INC·Filed 2013·Granted Oct 11, 2016·0 cites·17 claims
- 1267US2009123420A1Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-DioxygenaseMED COLLEGE GEORGIA RES INST·Filed 2008·Application pending·0 cites
- 1366US7763251B2Kits to assess the risk of tumor progressionMED COLLEGE GEORGIA RES INST·Filed 2006·Granted Jul 27, 2010·0 cites·3 claims
- 1464US2012141998A1Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune toleranceMELLOR ANDREW L·Filed 2012·Application pending·0 cites
- 1563US2013323832A1Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune toleranceGeorgia Health Sciences University·Filed 2013·Application pending·0 cites
- 1661US2012288472A1Regulation of t cell-mediated immunity by tryptophanMUNN DAVID·Filed 2012·Application pending·0 cites
- 1759US2005186289A1Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenaseMED COLLEGE GEORGIA RES INST·Filed 2004·Application pending·0 cites
- 1859US2010267042A1Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune ToleranceMELLOR ANDREW L·Filed 2010·Application pending·0 cites
- 1958US2009155311A1Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cellsMED COLLEGE OF GEORGIA RES INS·Filed 2007·Application pending·0 cites
- 2054US2009297540A1Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereofMELLOR ANDREW·Filed 2006·Application pending·0 cites
- 2153US2012142750A1Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cellsCHEN WEI·Filed 2011·Application pending·0 cites
- 2248US2010055111A1Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cellsMED COLLEGE OF GEORGIA RES INS·Filed 2008·Application pending·0 cites
- 2347US2009041787A1Chemokine receptor antagonists as therapeutic agentsMUNN DAVID H·Filed 2008·Application pending·0 cites
- 2446US2003194803A1Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune toleranceFiled 2002·Application pending·0 cites
- 2546US2013236456A1IMMUNOGLOBULIN Fc FRAGMENT TAGGING ACTIVATION OF ENDOGENOUS CD4 AND CD8 T CELLS AND ENHANCEMENT OF ANTITUMOR EFFECTS OF LENTIVECTOR IMMUNIZATIONHE YUKAI·Filed 2013·Application pending·0 cites
- 2646US2018008688A1Method and compositions for enhancing immunotherapeutic treatment of a cancerUNIV RES INST INC AUGUSTA·Filed 2017·Application pending·0 cites
- 2744US2014234373A1Methods of Promoting Immune ToleranceGEORGIA REGENTS UNIVERSITY·Filed 2012·Application pending·0 cites
- 2844US2011305713A1Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cellsMUNN DAVID H·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Munn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →